GNR-127 / Generium - LARVOL DELTA

A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis. (clinicaltrials.gov) - P1/2 | N=150 | Completed | Sponsor: AO GENERIUM | Active, not recruiting ➔ Completed

First-in-human • Trial completion • Allergic Rhinitis • Immunology • Inflammation

Pre-Seasonal Treatment With Recombinant Carrier-Based Birch Vaccine Improves Birch Pollen Allergy. (PubMed, Allergy) - P1/2 | "A pre-seasonal course of 5 monthly injections of GNR-127 80 μg improved symptoms of birch pollen allergy accompanied by a robust Bet v 1-specific IgG response, paving the road for a Phase III efficacy study."

Journal • Allergy • Hepatitis B • Immunology • Infectious Disease • Inflammation

A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis. (clinicaltrials.gov) - P1/2 | N=150 | Active, not recruiting | Sponsor: AO GENERIUM

New P1/2 trial • Allergic Rhinitis • Immunology • Inflammation